Makai is developing a portfolio of drug candidates that suppress TRPV1 activity through orally bioavailable antagonism or agonist-mediated desensitization..
We have completed in vitro mechanistic studies and in vivo proof of concept studies in murine models.
Makai BiotechnologY Business Development Strategy Overview
Makai Biotechnology is leveraging prior NIH funding for the in vitro and in vivo proof of concept stage to attract investment partnerships and submit an NIH SBIR fast track proposal.